TY - JOUR T1 - Impact of <sup>68</sup>Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1956 LP - 1961 DO - 10.2967/jnumed.117.192476 VL - 58 IS - 12 AU - Thomas A. Hope AU - Rahul Aggarwal AU - Bryant Chee AU - Dora Tao AU - Kirsten L. Greene AU - Matthew R. Cooperberg AU - Felix Feng AU - Albert Chang AU - Charles J. Ryan AU - Eric J. Small AU - Peter R. Carroll Y1 - 2017/12/01 UR - http://jnm.snmjournals.org/content/58/12/1956.abstract N2 - The purpose of this prospective study was to estimate the effect of 68Ga-labeled prostate-specific membrane antigen (PSMA)–11 PET on the intended management of patients with biochemically recurrent prostate cancer. Methods: Pre- and postimaging surveys were filled out by the referring providers for patients with biochemical recurrence who were imaged using 68Ga-PSMA-11 PET. The inclusion criterion for this study was a prostate-specific antigen (PSA) doubling time of less than 12 mo after initial treatment (NCT02611882). Of the 150 consecutive patients imaged, 126 surveys were completed (84% response rate). The responses were categorized as major change, minor change, no change, or unknown change. Results: There were 103 patients (82%) with disease detected on 68Ga-PSMA-11 PET. On the basis of the survey results, there were 67 patients (53.2%) with major changes in management and 8 patients (6.4%) with minor changes. The proportion of cases resulting in a change in management did not significantly differ by baseline PSA level. In patients with PSA levels below 0.2 ng/dL, 7 of 12 patients had disease detected on 68Ga-PSMA-11 PET, 5 of whom had a major change in management. Conclusion: 68Ga-PSMA-11 PET resulted in a major change in management in 53% of patients with biochemical recurrence. Further studies are warranted to investigate whether PSMA-based management strategies result in improved outcomes for patients. ER -